Abstract
Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Current Enzyme Inhibition
Title: Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Volume: 6 Issue: 2
Author(s): Hai-Chun Yang, Yiqin Zuo and Agnes B. Fogo
Affiliation:
Keywords: TGF-β, kidney, fibrosis
Abstract: Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Export Options
About this article
Cite this article as:
Yang Hai-Chun, Zuo Yiqin and B. Fogo Agnes, Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?, Current Enzyme Inhibition 2010; 6 (2) . https://dx.doi.org/10.2174/157340810791233042
DOI https://dx.doi.org/10.2174/157340810791233042 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Investigation of Cytotoxic Effects of Oxymetazoline on Lungs in a Rat Model of Rhinitis Medicamentosa
Current Molecular Pharmacology Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis
Current Vascular Pharmacology The Role of PDE5-Inhibitors in Cardiopulmonary Disorders: From Basic Evidence to Clinical Development
Current Medicinal Chemistry Mechanical Circulatory Support in Children
Current Cardiology Reviews Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Pitavastatin and 4-Hydroxy-3-Methoxyacetophenone (HMAP) Reduce Cognitive Dysfunction in Vascular Dementia During Experimental Diabetes
Current Neurovascular Research The Association Between HIV/AIDS During Pregnancy and Fetal Growth Parameters in Florida: A Population Based Study
Current HIV Research Prediction Models and Scores in Pulmonary Hypertension: A Review
Current Pharmaceutical Design Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
Current Neurovascular Research The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets COX-2 and the Kidneys
Current Pharmaceutical Design Metabolic Syndrome During Menopause
Current Vascular Pharmacology Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Nephro-Protective Effect of Cortex Lycii Radicis Extracts in Streptozotocin- Induced Diabetic Rats
Current Signal Transduction Therapy Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema
Current Diabetes Reviews